USO DE ANTICORPOS MONOCLONAIS POR PACIENTES COM COVID-19 INTERFERE NA CONCENTRAÇÃO SÉRICA DE ANGIOTENSINA II?

Abstract

Introduction: once the mechanisms of Sars-Cov-2 pathogenesis were known, several treatment methods for COVID-19 were developed, among them the use of monoclonal antibodies for the context of patients in severe stages of the disease stands out. Objective: to understand whether the use of monoclonal antibodies to treat severe COVID-19 interferes with serum levels of angiotensin II. Methodology: To carry out this research, the descriptors "COVID-19", "Angiotensin II", and "Antibodies, Monoclonal" and their respective "entry terms" suggested by the MeSH database were selected through DeCS and MeSH. Subsequently, using the Boolean operators OR and AND, a search strategy was set up, which was used in the PUBMED, EMBASE, Web of Science, Cochrane Library, and Scopus databases, without the restriction of publication date or language. Results: at the end of the article selection process, 29 were selected for full reading and analysis. In this review, different types of monoclonal antibodies were addressed, which were opportunely grouped according to their mechanism of action. Conclusion: it was possible to conclude that of the five classes of monoclonal antibodies treated in this work, three potentially can cause alterations in the serum levels of angiotensin II.